Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03927300
Other study ID # KM-00153
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 17, 2019
Est. completion date December 11, 2019

Study information

Verified date March 2020
Source Tmm Software
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The investigators proposed to conduct a retrospective study to evaluate the impact of the implementation of apTeleCare software on the management of dialysis patients at home in terms of the number and duration of hospitalizations. For this purpose, the investigators will compare patients' data over a 2-year interval before the introduction of Telemonitoring (January 2012 and December 2013 inclusive - Group 1) with patients data who have benefited from this application (between August 2016 and July 2018).


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date December 11, 2019
Est. primary completion date July 17, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients (= 18 years) with no age limit;

- Patients receiving peritoneal dialysis on the investigation center between 2012 and 2014 (Group1) and between 2016 and 2018 (Group 2);

- Patient information in this retrospective study;

Exclusion Criteria:

- Patients who have started a peritoneal dialysis program before the periods of investigation;

- Patients who have been equipped with apTeleCare during the dialysis program;

- Subject under guardianship, curators or safeguard of justice;

- Patient not affiliated to a French social protection;

Study Design


Intervention

Device:
Telemonitoring Software
Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.

Locations

Country Name City State
France Matthieu Merlot Montpellier

Sponsors (2)

Lead Sponsor Collaborator
Tmm Software Centre Hospitalier de Vichy

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative duration (on retrospective two years of follow-up) of the unscheduled hospitalizations between the two patient groups. up to two years.
Primary Cumulative duration (on retrospective two years of follow-up) of the scheduled hospitalizations between the two patient groups. up to two years.
Secondary Total length of hospitalisation For both groups. Every two months (follow-up visit) on a retrospective period of two years, the outcome 2 will be measured. The study duration will be of 5 months
Secondary Number of events of cardiovascular complications For both groups. Every two months (follow-up visit) on a retrospective period of two years. The study duration will be of 5 months
Secondary Mortality rate For both groups. At the end of this retrospective study (Study Period of 5 months).
Secondary Rate of peritoneal infections For both groups. At the end of this retrospective study.(Study Period of 5 months).
Secondary Number of patient exit technique except death For example transplant, hemodialysis For both groups. At the end of this retrospective study. (Study Period of 5 months).
Secondary Charlson score : Comorbidity index This scale measure the comorbidity symptoms of patients at the beginning of the care by the physician. The minimum score will be "0" and the maximum will be 39.
Its validation is based on a prediction of health French insurance, as well as on several clinical areas such as oncology or nephrology.
baseline
See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3